Skip to content

A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia

Status
Terminated
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02854670
Acronym
CAPSIVU
Enrollment
10
Registered
2016-08-03
Start date
2016-01-20
Completion date
2021-02-03
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vestibulodynia

Keywords

capsaicin, pain improvement, provoked vulvodynia

Brief summary

This study aims to assess the pain on contact in provoked vestibulodynia, measured with Visual Analogic Scale at week 0/week 2/week 6/week 12 after applying a patch of capsaicin.

Interventions

After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Provoked vulvodynia, rated B2a according to 2003 International Society for the Study of Vulvovaginal Disease (ISSVD) classification * Pain ≥ 4 on Visual Analogic Scale (VAS) * Subject refractory to at least 2 conventional treatments (tricyclic antidepressants, anticonvulsants at analgesic doses , biofeedback physical therapy, psychological assessment in a context of chronic pain) or to botulinum toxin A * If a former treatment with botulinum toxin A was performed: patient must be in treatment failure (= no decrease over 50% of the pain 3 months after initiation of the treatment) * Negative screening test results * Menopause, surgically sterilized women or women using effective contraceptive method * Good understanding and predictable adherence to the protocol * Beneficiary/affiliated to French social security/social healthcare * Signed Informed Consent Form

Exclusion criteria

* Predictable poor adherence * Pregnant or breastfeeding women * Diabetes mellitus type 1 or type 2 * Major mental disorders * Underlying etiology such as chronic vulvar disease * Initial vulvar erythema * Vulnerable subjects (particularly adults under guardianship) * Ongoing medical treatment with tricyclic antidepressants or anticonvulsants at analgesic doses Subject refractory to conventional treatments (tricyclic antidepressants and benzodiazepines doses analgesics, physiotherapy type of biofeedback) Good understanding and predictable adherence to the protocol beneficiary/affiliated to French social security/social healthcare signed Informed Consent Form

Design outcomes

Primary

MeasureTime frameDescription
Pain assessment with Visual Analogic Scale (using a q-tip)week 12Assessment of provoked pain with Visual Analogic Scale (using a q-tip)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026